Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Federal Medicaid Cuts
  • Generic Drugs
  • High-Deductible Plans
  • Gun Violence Trauma
  • Hospital Nutrition

WHAT'S NEW

  • Federal Medicaid Cuts
  • Generic Drugs
  • High-Deductible Plans
  • Gun Violence Trauma
  • Hospital Nutrition

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Monday, Oct 19 2020

Full Issue

No Vaccine Application From Pfizer Before The Election, CEO Says

Pfizer CEO Albert Bourla says his company's mid-October target to apply for FDA emergency use authorization for its COVID-19 vaccine candidate has shifted to mid-November, at the earliest.

AP: Pfizer: Mid-November Earliest It Can Seek Virus Vaccine OK

Pfizer Inc. cannot request emergency authorization of its COVID-19 vaccine before the third week of November -- and that’s if everything goes well, the company’s CEO announced Friday. Despite President Donald Trump’s repeated promises of a vaccine before Election Day, scientists have been cautioning that it’s unlikely data showing a leading shot actually works would come until November or December. (10/16)

Stat: Pfizer Won't Seek Covid-19 Vaccine Approval Before Mid-November 

An analysis of the efficacy of the vaccine could be available sooner, the company said in an open letter from its CEO, Albert Bourla, but required safety data will take longer. The timelines included in the letter are not new, based on disclosures the company has previously made about the status of its vaccine effort with the German biotechnology firm BioNTech. But the need for Bourla, who had previously said a vaccine could be available by October, to make a public announcement emphasizes the tense political conditions surrounding the race for a vaccine. (Herper, 10/16)

The New York Times: Pfizer Says It Won’t Seek Vaccine Authorization Before Mid-November

Close watchers of the vaccine race had already known that Pfizer wouldn’t be able to meet the requirements of the Food and Drug Administration by the end of this month. But Friday’s announcement represents a shift in tone for the company and its leader, who has repeatedly emphasized the month of October in interviews and public appearances. In doing so, the company had aligned its messaging with that of [President Trump], who has made no secret of his desire for an approved vaccine before the election. (Thomas and Weiland, 10/18)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Tuesday, May 5
  • Monday, May 4
  • Friday, May 1
  • Thursday, April 30
  • Wednesday, April 29
  • Tuesday, April 28
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF